Valuation: Outlook Therapeutics, Inc.

Market Cap 194M 169M 157M 144M 273M 18.56B 277M 1.85B 728M 9.24B 730M 714M 30.99B P/E 2026 *
-2.06x
P/E 2027 * -5.05x
Enterprise Value 194M 169M 157M 144M 273M 18.56B 277M 1.85B 728M 9.24B 730M 714M 30.99B EV / Sales 2026 *
47.2x
EV / Sales 2027 * 3.35x
Free-Float
85.03%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Outlook Therapeutics, Inc.

1 day-6.10%
1 week-26.02%
Current month-38.58%
1 month-38.58%
3 months+290.64%
6 months+122.11%
Current year-38.19%
1 week 0.82
Extreme 0.82
1.42
1 month 0.82
Extreme 0.82
1.87
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
34.6
5 years 0.16
Extreme 0.1611
65.4
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Chief Executive Officer 60 03/12/2024
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 60 02/08/2018
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Date Insider Type Main position Quantity % Market Cap.
7/29/26 A Buy

Chairman

95,398 0.0642%
7/21/26 A Free

Chief Executive Officer

100,000 0.0673%
7/21/26 A Free

Chief Financial Officer

210,078 0.1414%
Change 5-day change 1-year change 3-year change Capi.($)
-6.10%-26.02%-52.36%-97.06% 194M
-1.40%+3.69%-2.09%+11.41% 49.37B
-2.41%-0.65%+406.63%+629.40% 40.85B
-1.16%+13.36%+22.70%+3.92% 39.14B
-1.88%-3.29%+5.36%+40.37% 35.81B
-1.74%+8.42%+8.85%+48.87% 30.5B
-2.85%-3.46% - - 16.55B
-0.21%-4.74%+31.83%+126.49% 16.14B
-0.64%+3.09%+3.15%+9.37% 13.71B
-1.19%-3.97%-9.88%-35.13% 12.77B
Average -1.96%+2.67%+46.02%+81.96% 25.5B
Weighted average by Cap. -1.60%+6.69%+76.65%+130.27%

Financials

2026 *2027 *
Net sales 4.12M 3.58M 3.34M 3.06M 5.78M 393M 5.87M 39.31M 15.43M 196M 15.48M 15.14M 657M 58M 50.42M 46.93M 43.08M 81.36M 5.54B 82.62M 553M 217M 2.76B 218M 213M 9.24B
Net income -47.92M -41.66M -38.77M -35.6M -67.23M -4.57B -68.27M -457M -179M -2.28B -180M -176M -7.64B -32.34M -28.12M -26.17M -24.03M -45.37M -3.09B -46.08M -308M -121M -1.54B -121M -119M -5.15B
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
31/07/26 $0.9766 -6.10% 8,074,274
30/07/26 $1.040 +4.00% 9,921,218
29/07/26 $1.000 +10.62% 28,546,582
28/07/26 $0.9040 -15.12% 34,871,066
27/07/26 $1.065 -24.20% 40,412,061
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9766USD
Average target price
5.400USD
Spread / Average Target
+452.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock